A Rapid Systematic Review of U.S. Food and Drug Administration-Authorized COVID-19 Treatments.

ABSTRACT:

Background

The coronavirus disease 2019 (COVID-19) pandemic era saw numerous treatments authorized for emergency use by the United States (US) Food and Drug Administration (FDA). The purpose of the review was to determine if convalescent plasma, antivirals, or monoclonal antibodies are associated with serious adverse events (SAEs) and, if so, which specific populations are at risk.

Methods

PubMed, ClinicalTrials.gov, and the FDA submission database were searched through December 2023, and the Infectious Diseases Society of America guidelines, international COVID Network Meta-analysis database, and systematic reviews were reference mined to identify controlled studies with at least 1 US site. Reviewers abstracted study characteristics, number of patients experiencing each typ

SUBMITTER: Maglione MA 

PROVIDER: S-EPMC11986950 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature